(Q38958797)

English

Intranasal proteosome-based respiratory syncytial virus (RSV) vaccines protect BALB/c mice against challenge without eosinophilia or enhanced pathology

scientific article published on 24 May 2007

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

8 September 2017

Intranasal proteosome-based respiratory syncytial virus (RSV) vaccines protect BALB/c mice against challenge without eosinophilia or enhanced pathology (English)

1 reference

Europe PubMed Central

8 September 2017

author name string

Sonya L Cyr

1

1 reference

Europe PubMed Central

8 September 2017

Taff Jones

2

1 reference

Europe PubMed Central

8 September 2017

Ioana Stoica-Popescu

3

1 reference

Europe PubMed Central

8 September 2017

Angela Brewer

4

1 reference

Europe PubMed Central

8 September 2017

Sophie Chabot

5

1 reference

Europe PubMed Central

8 September 2017

Michelle Lussier

6

1 reference

Europe PubMed Central

8 September 2017

David Burt

7

1 reference

Europe PubMed Central

8 September 2017

Brian J Ward

8

1 reference

Europe PubMed Central

8 September 2017

language of work or name

0 references

publication date

24 May 2007

1 reference

Europe PubMed Central

8 September 2017

number of pages

12

1 reference

based on heuristic

inferred from page(s)

1 reference

Europe PubMed Central

8 September 2017

25

1 reference

Europe PubMed Central

8 September 2017

5378-5389

1 reference

Europe PubMed Central

8 September 2017

29

1 reference

Europe PubMed Central

8 September 2017

Respiratory syncytial virus inhibits granulocyte apoptosis through a phosphatidylinositol 3-kinase and NF-kappaB-dependent mechanism

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.004

7 January 2021

Pathophysiological mechanisms for the respiratory syncytial virus-reactive airway disease link

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.004

7 January 2021

Prolonged production of TNF-alpha exacerbates illness during respiratory syncytial virus infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.004

7 January 2021

Neurotrophin overexpression in lower airways of infants with respiratory syncytial virus infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.004

7 January 2021

An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.004

7 January 2021

Vaccine-enhanced respiratory syncytial virus disease in cotton rats following immunization with Lot 100 or a newly prepared reference vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.004

7 January 2021

Both immunisation with a formalin-inactivated respiratory syncytial virus (RSV) vaccine and a mock antigen vaccine induce severe lung pathology and a Th2 cytokine profile in RSV-challenged mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.004

7 January 2021

Respiratory syncytial virus (RSV) G glycoprotein is not necessary for vaccine-enhanced disease induced by immunization with formalin-inactivated RSV.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.004

7 January 2021

Association between severe respiratory syncytial virus infection and IL13/IL4 haplotypes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.004

7 January 2021

Inhibition of T1/ST2 during respiratory syncytial virus infection prevents T helper cell type 2 (Th2)- but not Th1-driven immunopathology

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.004

7 January 2021

Enhanced disease and pulmonary eosinophilia associated with formalin-inactivated respiratory syncytial virus vaccination are linked to G glycoprotein CX3C-CX3CR1 interaction and expression of substance P

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.004

7 January 2021

Aluminium compounds for use in vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.004

7 January 2021

Vaccine adjuvants: current state and future trends

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.004

7 January 2021

A potential molecular mechanism for hypersensitivity caused by formalin-inactivated vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.004

7 January 2021

Molecular analysis of respiratory syncytial virus reinfections in infants from coastal Kenya

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.004

7 January 2021

Immunity to and frequency of reinfection with respiratory syncytial virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.004

7 January 2021

Adjuvants recognized by toll-like receptors inhibit the induction of polarized type 2 T cell responses by natural attachment (G) protein of respiratory syncytial virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.004

7 January 2021

Cellular immunity and lung injury in respiratory virus infection.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.004

7 January 2021

Targeting of nasal mucosa-associated antigen-presenting cells in vivo with an outer membrane protein A derived from Klebsiella pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.004

7 January 2021

A novel and effective intranasal immunization strategy for respiratory syncytial virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.004

7 January 2021

Complete protection of mice from respiratory syncytial virus infection following mucosal delivery of synthetic peptide vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.004

7 January 2021

A nasal Proteosome influenza vaccine containing baculovirus-derived hemagglutinin induces protective mucosal and systemic immunity.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.004

7 January 2021

Nasal immunization with subunit proteosome influenza vaccines induces serum HAI, mucosal IgA and protection against influenza challenge

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.004

7 January 2021

A novel intranasal Protollin-based measles vaccine induces mucosal and systemic neutralizing antibody responses and cell-mediated immunity in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.004

7 January 2021

Safety and immunogenicity of a proteosome-Shigella flexneri 2a lipopolysaccharide vaccine administered intranasally to healthy adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.004

7 January 2021

Protollin: a novel adjuvant for intranasal vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.004

7 January 2021

Intranasal immunisation with inactivated RSV and bacterial adjuvants induces mucosal protection and abrogates eosinophilia upon challenge.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.004

7 January 2021

Purification and characterization of simian immunodeficiency virus (SIVmac) envelope glycoprotein gp130 from virus-infected cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.004

7 January 2021

Shifting immunodominance pattern of two cytotoxic T-lymphocyte epitopes in the F glycoprotein of the Long strain of respiratory syncytial virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.004

7 January 2021

The attachment (G) glycoprotein of respiratory syncytial virus contains a single immunodominant epitope that elicits both Th1 and Th2 CD4+ T cell responses.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.004

7 January 2021

Role of CCL11 in eosinophilic lung disease during respiratory syncytial virus infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.004

7 January 2021

Differential induction of the toll-like receptor 4-MyD88-dependent and -independent signaling pathways by endotoxins

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.004

7 January 2021

Upregulation of costimulatory molecules induced by lipopolysaccharide and double-stranded RNA occurs by Trif-dependent and Trif-independent pathways.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.004

7 January 2021

Involvement of toll-like receptor 4 in innate immunity to respiratory syncytial virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.004

7 January 2021

Respiratory syncytial virus-induced activation of nuclear factor-kappaB in the lung involves alveolar macrophages and toll-like receptor 4-dependent pathways

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.004

7 January 2021

Respiratory syncytial virus up-regulates TLR4 and sensitizes airway epithelial cells to endotoxin.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.004

7 January 2021

A subset of Toll-like receptor ligands induces cross-presentation by bone marrow-derived dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.004

7 January 2021

The ins and outs of cross-presentation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.004

7 January 2021

Respiratory syncytial virus (RSV)-induced airway hyperresponsiveness in allergically sensitized mice is inhibited by live RSV and exacerbated by formalin-inactivated RSV.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.004

7 January 2021

Microparticle vaccine approaches to stimulate mucosal immunisation.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.004

7 January 2021

Mucosal vaccines: the promise and the challenge

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.004

7 January 2021

Passive protection against respiratory syncytial virus disease in infants: the role of maternal antibody.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.004

7 January 2021

Treatment with anti-LFA-1 delays the CD8+ cytotoxic-T-lymphocyte response and viral clearance in mice with primary respiratory syncytial virus infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.004

7 January 2021

The outcome of 26 patients with respiratory syncytial virus infection following allogeneic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.004

7 January 2021

Cell-mediated adaptive immune defense of the lungs

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.004

7 January 2021

Antigen-dependent proliferation and cytokine induction in respiratory syncytial virus-infected cotton rats reflect the presence of effector-memory T cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.004

7 January 2021

Cellular immunity and memory to respiratory virus infections

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.004

7 January 2021

Enhanced pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of interleukin-4 (IL-4) and IL-10.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.004

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2007.05.004

1 reference

Europe PubMed Central

8 September 2017

1 reference

Europe PubMed Central

8 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38958797&oldid=1799140587"